(24/7 MARKET NEWS) – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) reported, after yesterday’s market close, that the United States Patent and Trademark Office (USPTO) allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia’s newly allowed U.S. Patent Application (No. 17/713,140) reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS.
Aurinia Pharmaceuticals is trading at $8.70, up $0.49 (+5.97%), on volume of 720 thousand shares traded.
Its 52-week range is $4.07 to $20.4752. It bounced off its low about a month ago and appears to be moving higher in a nice orderly fashion. Its next key inflection points are approximately $10, $12, and $13. If can break through the $13 resistance level, on stronger volume, it could try to challenge its February trading levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
